Since China, Canada and Mexico are the U.S.’ biggest trade partners, it should come as no surprise that they have the most import alerts involving U.S. FDA-regulated products. Read More

SHANGHAI – Few people are as well placed to understand the financing situation of China’s biomedicine sector than Mike Braun, managing partner for Deloitte’s Life Science & Health Financial Advisory Services in China. Read More

BEIJING – At the recent China Trials: Global Clinical Trial Summit here, a confab of chief scientists and contract research organization (CRO) leaders declared that China needs to be elevated and considered much earlier in global trials design. Read More

HONG KONG – A leading UK-based cancer drug developer and a Chinese university research institute have announced plans to work together to develop a new leukemia drug that may have a number of other uses. Read More

• Gland Pharma Ltd., of Mumbai, India, said KKR, a global investment firm, will acquire a minority stake in the generics company for approximately $200 million, including KKR’s acquisition of the entire stake held by Evolvence India Life Sciences Fund, an existing private equity investor in Gland Pharma. Read More

• Viralytics Ltd., of Sydney, appointed Keith Flaherty to its scientific advisory board. Flaherty is director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital Cancer Center and associate professor of medicine at Harvard Medical School. Read More

BioWorld’s offices were closed Thursday, Nov. 28, and Friday, Nov. 29, in observance of the Thanksgiving Day holiday in the U.S. No issues were published those days. Read More